2009
DOI: 10.1016/j.clnu.2009.05.013
|View full text |Cite
|
Sign up to set email alerts
|

Decreased food intake is a risk factor for mortality in hospitalised patients: The NutritionDay survey 2006

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

23
309
4
55

Year Published

2010
2010
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 396 publications
(398 citation statements)
references
References 30 publications
23
309
4
55
Order By: Relevance
“…Hiesmayr et al 12 studied a European population and found that low food intake was an independent risk factor for mortality. However, this was a one-day cross-sectional study, and it did not assess long term outcomes.…”
Section: Introductionmentioning
confidence: 99%
“…Hiesmayr et al 12 studied a European population and found that low food intake was an independent risk factor for mortality. However, this was a one-day cross-sectional study, and it did not assess long term outcomes.…”
Section: Introductionmentioning
confidence: 99%
“…Implementation of nutritional support strategies into daily clinical practice encounters many difficulties and considerable efforts are needed to be successful (Hiesmayr et al, 2009;Schindler et al, 2010). To facilitate this process, guidelines provided by the American and European Nutritional Societies may be helpful.…”
Section: Introductionmentioning
confidence: 99%
“…This is particularly related to the fact that even severe pre-existing comorbidities, like cardiovascular disease, pulmonary restrictions, impaired renal function and malnutrition, as well as age are no longer considered as contraindications for major GI surgery. There is increasing evidence that nutritional screening and therapy are important adjuncts in modern surgical care as 40% of surgical patients are malnourished (Bozzetti et al, 2007;Schiesser et al, 2008;Sorensen et al, 2008;Hiesmayr et al, 2009;Schindler et al, 2010).…”
Section: Introductionmentioning
confidence: 99%
“…30,31 The spectrum of CVD in the setting of breast cancer therapy includes congestive heart failure (CHF), myocardial ischemia, hypertension, arrhythmias, QT prolongation, bradycardia, pericarditis, acute coronary syndrome, and thromboembolic events (TEs). [31][32][33][34] Anthracyclines: Doxorubicin and Epirubicin: Anthracyclines bind to the DNA of malignant cells, interfering with the replication process and resulting in cellular death. Anthracycline therapy has been shown to increase the development of CHF and cardiomyopathy by 2%, [34][35][36][37][38][39] doubling to 4% if used in conjunction or sequence with trastuzumab.…”
Section: Chemotherapymentioning
confidence: 99%
“…[46][47][48] As with most chemotherapeutic agents, the risk of cardiotoxicity appears to be dose related. 33,47 In addition to dose, prior anthracycline therapy, a history of mediastinal radiation, and elderly age are further risk factors for cardiotoxicity. 29,[45][46][47]49,50 Cytoskeletal …”
Section: Chemotherapymentioning
confidence: 99%